Veracyte, Inc. (12V.F)
Frankfurt · EUR · Healthcare · Diagnostics & Research
€45.52 (+5.37%) as of
Key statistics
- Market cap
- 3.66B
- P/E (TTM)
- 35.02
- Forward P/E
- -89.25
- EPS (TTM)
- 1.30
- Dividend yield
- 0.00%
- 52-week range
- 25.98 – 52.72
- Beta
- 1.95
- Revenue (TTM)
- 561.9M
- Profit margin
- 20.37%
- Volume
- 200.00
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- South San Francisco, CA, United States
- Employees
- 755
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.